Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus

Abstract

BackgroundType 2 diabetes mellitus (T2DM) and cancer are serious health problems worldwide, and their prevalences have been on the rise in recent years. It has been reported that adropin plays an important role in the development of T2DM, oxidative stress, inflammation, and obesity. However, there is limited information available on T2DM from human studies, especially for the Korean population. In this study, we aimed to investigate the correlation between adropin levels and obesity of Korean T2DM patients.MethodsThirty-six T2DM patients were recruited for this study. The participants were further classified into female (n = 12) and male (n = 24). Their body composition, metabolic parameters, inflammatory factors, and oxidative stress were measured.ResultsThe severity of obesity is more manifested in male than in female. Plasma triglyceride (TG) and high-sensitivity C-reactive protein (hs-CRP) levels of male were significantly higher than female. The plasma adropin and adiponectin level of female was significantly higher than male. The body weight, body mass index (BMI), body fat mass were negatively correlated with the plasma adropin level in female, whereas adropin has positive correlation with adiponectin in female. The hs-CRP was negatively correlated with the plasma adropin level in female and male. malondialdehyde, reactive oxidative species, and TNF-α was not significantly correlated with adropin in patients with T2DM.ConclusionsThese findings suggest that adropin may be more used as a biomarker for predicting the risk of obesity and inflammation in Korean patients with T2DM, especially women.

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research

“…In contrast, in mice with high-fat diet-induced obesity, serum adropin levels are low (<1 ng/mL). An inverse correlation of adropin levels and body mass index (BMI) was also confirmed by human studies [4,[12][13][14][15][16][17]], suggesting that a low level of adropin is a hallmark of obesity. Nevertheless, a recent detailed study showed that this association should be interpreted cautiously.…”

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

“…Adropin levels correlated negatively with fasting plasma glucose (FPG), HOMA2‐IR, triglycerides, haemoglobin A1c (HbA1c), body mass index (BMI) and high‐sensitivity C‐reactive protein (hs‐CRP) and positively with high‐density lipoprotein cholesterol (HDL‐C) 22 . Adropin levels were higher in T2D females than males 23 …”

Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

“…Physiological serum adropin levels are still poorly defined, however, the adropin concentration in blood depends on a well-defined factors. Low adropin levels are strongly associated with pathological conditions such as insulin resistance, which is independent of the presence of obesity, dyslipidemia, hepatic steatosis, or increased fat mass ( 7 ). Overexpression or exogenous administration of adropin improves glucose homeostasis and increases capillary density and blood flow in mouse hind limb ischemia models ( 8 ).…”